Company intelligence / Profile preview

Strand Research

Boston, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~150
Development stage: Preclinical

Overview

Strand Therapeutics has developed a proprietary programmable mRNA technology that enables precise control of protein expression in targeted cells. Its lead program, STX‑001, entered Phase 1/2 clinical trials in April 2024 for advanced solid tumors. The company’s approach allows for long-lasting and cell-specific therapeutic effects with applications in oncology and potentially other disease areas. Early results focus on safety and immune activation within tumor microenvironments; broader efficacy data are pending as trials progress.[3]

Therapeutic areas: OncologyRare DiseasesHematology
Modalities: mRNA therapeuticsCAR-T
Industry: Biotech

Partnerships

Open to pharma partnerships; no major deals publicly disclosed yet as of May 2025.[1][3]

Beyond the preview

Go deeper on Strand Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Strand Research.

Explore the full profile